JP2009521521A5 - - Google Patents

Download PDF

Info

Publication number
JP2009521521A5
JP2009521521A5 JP2008548072A JP2008548072A JP2009521521A5 JP 2009521521 A5 JP2009521521 A5 JP 2009521521A5 JP 2008548072 A JP2008548072 A JP 2008548072A JP 2008548072 A JP2008548072 A JP 2008548072A JP 2009521521 A5 JP2009521521 A5 JP 2009521521A5
Authority
JP
Japan
Prior art keywords
buffer
composition
kit
solution
thiol protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008548072A
Other languages
English (en)
Japanese (ja)
Other versions
JP5435955B2 (ja
JP2009521521A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2006/001492 external-priority patent/WO2007074454A2/en
Publication of JP2009521521A publication Critical patent/JP2009521521A/ja
Publication of JP2009521521A5 publication Critical patent/JP2009521521A5/ja
Application granted granted Critical
Publication of JP5435955B2 publication Critical patent/JP5435955B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008548072A 2005-12-27 2006-12-27 安定な酵素製剤及びその使用方法 Expired - Fee Related JP5435955B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75340005P 2005-12-27 2005-12-27
US60/753,400 2005-12-27
PCT/IL2006/001492 WO2007074454A2 (en) 2005-12-27 2006-12-27 Stable enzymatic preparations and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2009521521A JP2009521521A (ja) 2009-06-04
JP2009521521A5 true JP2009521521A5 (cg-RX-API-DMAC7.html) 2010-02-12
JP5435955B2 JP5435955B2 (ja) 2014-03-05

Family

ID=37943776

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008548072A Expired - Fee Related JP5435955B2 (ja) 2005-12-27 2006-12-27 安定な酵素製剤及びその使用方法

Country Status (6)

Country Link
US (2) US8197808B2 (cg-RX-API-DMAC7.html)
EP (1) EP1965763B1 (cg-RX-API-DMAC7.html)
JP (1) JP5435955B2 (cg-RX-API-DMAC7.html)
DK (1) DK1965763T3 (cg-RX-API-DMAC7.html)
ES (1) ES2763724T3 (cg-RX-API-DMAC7.html)
WO (1) WO2007074454A2 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8197808B2 (en) 2005-12-27 2012-06-12 Ramot At Tel-Aviv University Ltd. Stable enzymatic preparations and methods of use thereof
CN101588803B (zh) * 2006-12-06 2013-03-20 康乃尔研究基金会有限公司 中等持续时间神经肌肉阻断剂及其拮抗剂
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
WO2009152374A2 (en) 2008-06-12 2009-12-17 Medtronic Xomed, Inc. Method for treating chronic wounds
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CA2747703C (en) 2009-01-06 2021-06-15 Curemark Llc Compositions and methods for the treatment or the prevention of infections by e. coli
JP5684725B2 (ja) 2009-01-06 2015-03-18 キュレロン リミテッド ライアビリティ カンパニー 黄色ブドウ球菌感染の治療または予防のための組成物および方法ならびに表面上にいる黄色ブドウ球菌の根絶または低減のための組成物および方法
EP2226382A1 (en) 2009-03-03 2010-09-08 B.R.A.I.N. Biotechnology Research and Information Network AG Protease for wound conditioning and skin care
US8592451B2 (en) 2009-03-17 2013-11-26 Cornell University Reversible nondepolarizing neuromuscular blockade agents and methods for their use
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011022491A1 (en) * 2009-08-19 2011-02-24 Cornell University Cysteine for physiological injection
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
SG187534A1 (en) 2010-08-29 2013-03-28 Vascode Technologies Ltd A system and methods for multi-tasking in a clientless mobile phone
DK2701733T3 (da) 2011-04-21 2019-05-27 Curemark Llc Forbindelser til behandling af neuropsykiatriske forstyrrelser
JP5967675B2 (ja) * 2011-08-31 2016-08-10 ケーシーアイ ライセンシング インコーポレイテッド 減圧治療および創面切除用のシステムおよび方法
US20130202581A1 (en) * 2012-02-02 2013-08-08 Curelon Llc Enzyme compositions and use thereof for wound healing
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US11364286B2 (en) * 2015-10-14 2022-06-21 Newsouth Innovations Pty Limited Compositions and methods for the treatment of diseases involving mucin
CA3012299C (en) * 2016-01-31 2022-05-31 Mediwound Ltd. Debriding composition for treating wounds
NZ748416A (en) * 2016-04-18 2022-12-23 Mediwound Ltd Methods of debridement of chronic wounds
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
CA3199921A1 (en) * 2020-11-25 2022-06-02 Steven M. Hernandez Scar treatment composition
CN115998690B (zh) * 2022-11-10 2024-07-26 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB913203A (en) 1958-12-30 1962-12-19 Swift & Co Enzyme formulations for the production of tenderized meat
US3539451A (en) 1968-05-31 1970-11-10 Castle & Cooke Production of reversibly inactivated papain and ficin
US4307081A (en) 1974-01-08 1981-12-22 Gerold K. V. Klein Enzyme mixture
US4715899A (en) 1982-10-21 1987-12-29 Subir Chanda Liquid cleaner containing inactivated protease for protein soiled contact lenses
JPH0449299A (ja) 1990-06-14 1992-02-18 Tosoh Corp 免疫グロブリンフラグメントの精製法
DE4026591B4 (de) 1990-08-23 2005-08-25 Pleva Gmbh Vorrichtung zur Bestimmung der Beladung von Luft mit Dämpfen
JP2665639B2 (ja) 1992-01-09 1997-10-22 テーオー食品株式会社 安定化されたチオール蛋白分解酵素を含む焼き肉のタレ
US7364565B2 (en) 2001-07-27 2008-04-29 Ramot At Tel Aviv University Ltd. Controlled enzymatic removal and retrieval of cells
EP1446096A1 (en) 2001-11-13 2004-08-18 The Procter & Gamble Company Topical compositions containing enzymes stabilised with inhibitors
US6692726B1 (en) * 2003-02-11 2004-02-17 Colgate Palmolive Company Enzyme containing oral composition having enhanced stability
DE602004020910D1 (de) 2003-10-10 2009-06-10 Cosmedical Aps Haarwuchshemmung
US8197808B2 (en) 2005-12-27 2012-06-12 Ramot At Tel-Aviv University Ltd. Stable enzymatic preparations and methods of use thereof

Similar Documents

Publication Publication Date Title
Moore et al. Mechanisms of gastrointestinal ischemia‐reperfusion injury and potential therapeutic interventions: a review and its implications in the horse
ES2633574T3 (es) Formulaciones de antagonistas de VEGF
US7713929B2 (en) Rapid acting and long acting insulin combination formulations
Pratt et al. Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers.
ES2256335T3 (es) Combinacines sinergisticas que comprenden un inhibidor de la renina para el tratamiento de enfermedades cardiovasculares.
JP2005508981A5 (cg-RX-API-DMAC7.html)
ES2709103T3 (es) Métodos para conservar órganos y tejidos
ES2324909T3 (es) Preparado con principio activo en forma de pelicula con mejora de la estabilidad quimica y procedimiento para su fabricacion.
Lieberman et al. Inhibitors and activators of leukocytic proteases in purulent sputum: Digestion of human lung and inhibition by alpha1-antitrypsin
Napolitano et al. Nonventilatory strategies for patients with life-threatening 2009 H1N1 influenza and severe respiratory failure
CA2275890A1 (en) Stable liquid interferon formulations
JP2010529018A5 (ja) 医薬組成物、および医薬錠剤
TWI751379B (zh) 用於遞送胜肽之藥物組合物
US20100239663A1 (en) Composition for foodstuff for binding acetaldehyde
JP2005529847A5 (cg-RX-API-DMAC7.html)
Dasta et al. Acetylcysteine as a cytoprotective antioxidant in patients with severe sepsis: potential new use for an old drug
JP2025163108A5 (cg-RX-API-DMAC7.html)
JP2009521521A (ja) 安定な酵素製剤及びその使用方法
JP2015513549A5 (cg-RX-API-DMAC7.html)
JP2023116498A5 (cg-RX-API-DMAC7.html)
ES2224917T1 (es) Composiciones farmaceuticas de agente fibrinolitico.
CA2723007A1 (en) Aqueous composition containing a metalloprotein
JP5892940B2 (ja) クラウン化合物及び/又は対イオンと複合体化されたペプチドを含む粘膜送達組成物
JP7158063B2 (ja) グルカゴン保護剤及びその応用
ES2697343T3 (es) Formulación de gel que comprende agentes analgésicos y anestésicos